All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Oral Anticoagulant Reversal Agents: Deconstructing the Clinical Data

A Breakfast Symposium to be Conducted at the 2019 ASHP Midyear Clinical Meeting & Exhibition

Tuesday, December 10, 2018, 6:15 AM - 7:45 AM PT
Mandalay Bay North Convention Center, South Pacific Ballroom E


Register to attend in Las Vegas 

Register to attend via Webinar 

Activity Description

Prior to the development of reversal agents for direct oral anticoagulants (DOACs), pharmacists and clinicians were left with little choice in managing acute major bleeding. Assessment of the severity of the bleed is a one of the first steps in determining if reversal of anticoagulation is necessary. After other initial measures are completed, should the clinician determine reversal to remain necessary, the decision on which reversal agent to use becomes critical. Fortunately, specific treatments have been developed to address this need and new data is continually becoming available to aid in the selection process.

The goal of this educational activity is to enhance the pharmacist’s knowledge of major bleeding types and assessment. Reversal agent selection and dosing strategies will be reviewed, along with the assessment of the latest safety and efficacy data. A discussion on reversal agent procurement and administration will provide learners with formulary development considerations. This will be an interactive session to include Q&A with the faculty, as well as audience-response polling and decision-making exercises.

Learning Objectives

The target audience for this activity includes health‐system pharmacists, including chief pharmacy officers and pharmacy directors. At the completion of this activity, the participant will be better able to:

  • Identify and assess patients with an acute major bleed in order to recommend appropriateness of oral anticoagulation reversal.
  • Demonstrate understanding of reversal agent selection and dosing strategies.
  • Discuss safety and efficacy data surrounding the use of oral anticoagulation reversal.
  • Examine practical considerations for the procurement and administration of oral anticoagulation reversal agents.


5:45 AM Registration and Breakfast
6:15 AM – 7:45 AM CE Activity
Pre-registration is encouraged, and will be used for planning purposes. Seating will be available on a first-come, first-served basis. On-site registration will be available, space permitting.


Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Professor of Pharmacy Practice and Science
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

Katelyn W. Sylvester, PharmD, CACP, BCPS
Pharmacy Manager – Anticoagulation Services
Department of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts

CE Accreditation


ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-503-L01-P has been assigned to this live knowledge-based activity (initial release date 12-10-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. Statements of completion will be issued online at and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. . Dr. Dobesh has served as a consultant for Boehringer Ingelheim, Janssen Pharmaceuticals, Pfizer/BMS Alliance, and Portola Pharmaceuticals. Dr. Sylvester has served as a consultant for Portola Pharmaceuticals. A portion of grant funds received by ProCE from Portola Pharmaceuticals, Inc. will be used to compensate the faculty for this presentation.


This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals, Inc.


Register to attend in Las Vegas 

Register to attend via Webinar 

Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.